NCT04781959 - A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy | Biotech Hunter

Enrollment

233

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

February 23, 2023

Study Completion Date

September 28, 2023

Conditions

Early-stage Breast Cancer

Interventions

DRUG

Filgrastim

Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy

DRUG

Pegfilgrastim

Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy

Trial Locations (2)

Ottawa Hospital Research Institute, Ottawa

Thunder Bay Regional Health Sciences Centre, Thunder Bay